Project Director, Dr. Kathleen Neuzil (CVDGH) is a globally recognized vaccinologist with proficiency ranging from epidemiology, international field trials and vaccine policy, to partnerships with emerging manufacturers and direct experience with Gavi processes, World Health Organization (WHO) policy, and prequalification (PQ). She has led successful multi-year, multi-site, efforts in global health, informing vaccine policy recommendations and catalyzing introductions. She brings a fresh perspective and objective approach necessary to mobilize the field and move typhoid conjugate vaccines (TCVs) forward.
Working closely with Dr. Neuzil will be Deputy Director, Dr. Andrew Pollard (Oxford) who is one of the leading typhoid experts in the world and brings considerable technical knowledge and experience in coordination of international typhoid networks and consortia. Dr. Pollard is Director of the Oxford Vaccine Group and is currently evaluating a TCV using a human challenge model. He chairs the United Kingdom’s National Immunization Technical Advisory Group (NITAG), the European Medicines Agency’s (EMAs) vaccine Scientific Advisory Group (SAG), and is a WHO Strategic Advisory Group of Experts (SAGE) member, bringing the knowledge and expertise necessary to lead and deliver on this complex project.
Dr. Anthony Marfin (PATH) will provide essential support to Drs. Neuzil and Pollard on the TyVAC project. Dr. Marfin brings decades of infectious disease experience, including 23 years at the US Centers for Disease Control and Prevention (CDC). He is a medical officer for PATH’s Center for Vaccine Innovation and Access (CVIA) and Director of the Japanese encephalitis (JE) vaccine projects, working closely with WHO, Gavi, and other global stakeholders to increase vaccine introduction. Dr. Marfin is a subject matter expert on yellow fever, JE, and other mosquito-borne viruses. He will leverage this leadership and expertise to increase uptake of TCVs as part of an integrated approach to prevent and control typhoid fever.